Abstract
AbstractTuberculosis, caused by Mycobacterium tuberculosis, remains a major public health concern, demanding new antibiotics with innovative therapeutic principles due to the emergence of resistant strains. Benzothiazinones (BTZs) have been developed to address this problem. However, an unprecedented in vivo biotransformation of BTZs to hydride-Meisenheimer complexes has recently been discovered. Herein, we present a study of the influence of electron-withdrawing groups on the propensity of HMC formation in whole cells for a series of C-6-substituted BTZs obtained through reductive fluorocarbonylation as a late-stage functionalization key step. Gibbs free energy of reaction and Mulliken charges and Fukui indices on C-5 at quantum mechanics level were found as good indicators of in vitro HMC formation propensity. These results provide a first blueprint for the evaluation of HMC formation in drug development and set the stage for rational pharmacokinetic optimization of BTZs and similar drug candidates.
Funder
Bundesministerium für Bildung und Forschung
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. World Health Organization. Global Tuberculosis Report 2022. (2022).
2. World Health Organization. WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment Drug-Susceptible Tuberculosis Treatment. (2022).
3. Furin, J., Cox, H. & Pai, M. Tuberculosis. Lancet 393, 1642–1656 (2019).
4. Fekadu, G., Tolossa, T., Turi, E., Bekele, F. & Fetensa, G. Pretomanid development and its clinical roles in treating tuberculosis. J. Glob. Antimicrob. Resist. 31, 175–184 (2022).
5. World Health Organization. WHO Operational Handbook on Tuberculosis Module 4: Treatment Drug-Resistant Tuberculosis Treatment. (2020).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献